Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.

[1]  Trevor J Pugh,et al.  Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer , 2020, Cancer.

[2]  H. Putter,et al.  Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Pasanen,et al.  Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma , 2020, Modern Pathology.

[4]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Gilks,et al.  Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas , 2019, The Journal of pathology.

[6]  R. Doghri,et al.  Mismatch Repair Deficiency in Endometrial Cancer: Immunohistochemistry Staining and Clinical Implications , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  J. McAlpine,et al.  Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. , 2019, Gynecologic oncology.

[8]  A. Psyrri,et al.  Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer , 2019, ESMO Open.

[9]  P. Goodfellow,et al.  Mismatch repair deficiency identifies patients with high‐intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker , 2018, Cancer.

[10]  M. Schiavi,et al.  Immunotherapy in endometrial cancer: new scenarios on the horizon , 2019, Journal of gynecologic oncology.

[11]  Yanjing Li,et al.  The practice of universal screening for Lynch syndrome in newly diagnosed endometrial carcinoma , 2018, Health science reports.

[12]  A. Spurdle,et al.  Endometrial cancer risk and survival by tumor MMR status , 2018, Journal of gynecologic oncology.

[13]  Wei Chen,et al.  Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. , 2017, Gynecologic oncology.

[14]  D. Tritchler,et al.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[16]  H. Yoshikawa,et al.  Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. , 2016, Gynecologic oncology.

[17]  H. Ngan,et al.  The Significance of Mismatch Repair Deficiency in Young Patients With Endometrial Cancer , 2015, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[18]  E. Lopez-Lopez,et al.  Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type. , 2014, Gynecologic oncology.

[19]  Alexander M. Metcalf,et al.  Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  X. Matías-Guiu,et al.  Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. , 2013, Critical reviews in oncology/hematology.

[21]  Colin C Pritchard,et al.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. , 2012, The Journal of molecular diagnostics : JMD.

[22]  F. Sinicrope.  DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer , 2010, Nature Reviews Clinical Oncology.

[23]  W. Frankel,et al.  Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer. , 2009, Gynecologic oncology.

[24]  P. Goodfellow,et al.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Tritchler,et al.  An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. , 2018, Gynecologic oncology.

[26]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[27]  D. Chang,et al.  The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch Syndrome: from bench to bedside , 2007, Familial Cancer.